Trial Profile
Open Label, Multi-Center, Randomized Safety, Feasibility and Tolerability Pilot Study of Pegasys (Peginterferon Alfa-2a) Copegus (Ribavirin) in Previous Intravenous Drug Users Who Are Currently Enrolled in a Methadone Maintenance Treatment Program
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- Sponsors Roche
- 04 Feb 2016 Change in treatment table: oral ribavirin 800 milligram (mg)/day (twice in a day) for 24 weeks for G2/3 added in treatments as per ClinicalTrials.gov record.
- 02 Jun 2010 New source identified and integrated (Roche)
- 26 Jun 2007 Status changed from in progress